(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |
|---|---|---|---|---|---|---|---|
| 3aox | EMH | Alectinib (DB11363) | Alectinib is a kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. | ALK TYROSINE KINASE RECEPTOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 4mkc | 4MK | Ceritinib (DB09063) | Ceritinib is an antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib. | ALK TYROSINE KINASE RECEPTOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 4tt7 | COM | Coenzyme m (DB09110) | Coenzyme M is a uroprotective agent used for the reduction and prophylaxis of oxazaphosphorine-induced toxicity in the urinary tract. | ALK TYROSINE KINASE RECEPTOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 5a9u | 5P8 | Lorlatinib (DB12130) | Lorlatinib is an anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. | ALK TYROSINE KINASE RECEPTOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 5fto | YMX | Entrectinib (DB11986) | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019... | ALK TYROSINE KINASE RECEPTOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6mx8 | 6GY | Brigatinib (DB12267) | Brigatinib is an anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. | ALK TYROSINE KINASE RECEPTOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |